290 results on '"Hee‐Kyung Ahn"'
Search Results
2. Muscling My Way to My Positive Future: Physical Exertion of Strength and Preference for Risk
- Author
-
Eunice Kim Cho and Hee-Kyung Ahn
- Subjects
physical strength ,risk preference ,sense of control ,illusory control ,risky choice ,Business ,HF5001-6182 - Abstract
Building on the growing literature on how physical bodily expressions influence psychological processes, the authors propose that exerting physical strength decreases risk perceptions and increases preference for risky options by increasing perceptions of control or agency. The present research is based on the belief of “no pain, no gain”, that when an individual exerts physical strength and effort, he believes he can be the agent in bringing about the desired outcome. Because of this automatic association between exerting physical strength and the sense of being in control of the outcome, the authors hypothesize that even in situations where the outcome is determined by chance and luck, individuals exerting effort feel they have more control and thus choose riskier, but more desirable, options. Furthermore, this research clarifies the distinction between physical exertion of strength, high- and low-power poses, and psychological power. more...
- Published
- 2020
- Full Text
- View/download PDF
Catalog
3. Happiness from What We Have and What We Experience: Attribute Non-alignability Increases Anticipated Satisfaction from Experiential Purchases
- Author
-
Minhee Kim and Hee-Kyung Ahn
- Subjects
material purchase ,experiential purchase ,deliberative processing ,intuitive processing ,alignability ,choice process satisfaction ,happiness ,Business ,HF5001-6182 - Abstract
This research examines how processing type and alignability moderate the effect of product type on satisfaction (i.e., happiness). It is well known that there are two types of processing―deliberative and intuitive processing. Based on the previous literature that the intuitive processing is compatible with experiential purchases and the deliberative processing is fit with material purchase, the current research demonstrates that processing type moderates the effect of product type on happiness. Moreover, we hypothesize that alignability moderates the effect of product type on anticipated satisfaction. As expected, participants in the intuitive processing condition reported greater happiness from their experiential purchases than material purchases. However, in the deliberative processing condition, there was no significant difference between happiness levels from material and experiential purchases. Furthermore, when the attributes of choice options were presented in a non-alignable manner, participants reported greater anticipated satisfaction from experiential purchases than from material purchases. However, this difference disappeared when attributes were presented in an alignable manner. Finally, we propose ‘choice process’ satisfaction as a potential mediator of the moderating effect of processing type on the relationship between product type and (anticipated) satisfaction. more...
- Published
- 2020
- Full Text
- View/download PDF
4. Counting Up while Doing Tasks Makes You Feel More Difficult than Counting Down
- Author
-
Hee-Kyung Ahn
- Subjects
vertical progress ,embodied cognition ,persistence ,motivation ,goal pursuit ,self-regulation ,Business ,HF5001-6182 - Abstract
In this research, we explore whether mere exposure to external cues with vertical progress (e.g., moving upward or moving downward) can influence individuals’ persistence to complete focal tasks. Drawing on the theory of embodied cognition, we propose that, a moving-upward (vs. downward) cue activates the abstract concept of difficulty, which is associated with the physical experience of climbing uphill (vs. downhill). Due to this association between moving uphill and difficulty, merely exposing individuals to the moving-upward cue can induce greater feeling of difficulty and this greater difficulty, in turn, reduce individuals’ persistence, compared to exposing individuals to the moving-downward cue. Across three studies, we find supporting evidence for the effect of the external cues with vertical progress on individuals’ performance both in physical tasks and in a cognitive task. more...
- Published
- 2015
- Full Text
- View/download PDF
5. Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies
- Author
-
Konstantin Penkov, Igor Bondarenko, Daria Viktorovna Saenko, Yaroslav Kulyaba, Jun Guo, Yi Gong, Noboru Yamamoto, Yevhen Stepanovych Hotko, Vasyl Boyko, Natalya Vladimirovna Fadeeva, Grygorii Mykolaiovych Ursol, Hee Kyung Ahn, Nikolay Viktorovich Kislov, Chia-I Shen, Craig Davis, Karey Kowalski, Elisabete Michelon, Dmitri Pavlov, Tomoko Hirohashi, and Byoung Chul Cho more...
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Sasanlimab (PF-06801591), a humanized immunoglobulin G4 monoclonal antibody, binds to programmed cell death protein-1 (PD-1), preventing ligand (PD-L1) interaction. Objectives: To evaluate pharmacokinetics (PK), safety, tolerability, and efficacy of two subcutaneous sasanlimab dosing regimens. Design: An open-label study consisting of phases Ib and II. Phase Ib: non-randomized, dose escalation, and expansion study in Asian participants with advanced malignancies. Phase II: conducted globally in participants with non-small-cell lung cancer with PD-L1 positive or PD-L1 status unknown tumors; participants were randomized 1:2 to receive subcutaneous sasanlimab 300 mg once every 4 weeks (300 mg-Q4W) or 600 mg once every 6 weeks (600 mg-Q6W). Methods: Primary endpoint in phase Ib: dose-limiting toxicity (DLT) occurring in first treatment cycle; in phase II: C trough and AUC. Results: A total of 155 participants (phase Ib, n = 34; phase II, n = 121) received sasanlimab. Phase Ib: no DLT reported. Phase II: ratio of adjusted geometric mean for AUC tau was 231.2 (90% CI, 190.1–281.2) and C trough was 111.5 (90% CI, 86.3–144.0) following 600 mg-Q6W (test) versus 300 mg-Q4W (reference). Phase Ib: grade 3 treatment-related adverse events (TRAEs) occurred in 1/4 (25%) and 3/12 (25%) participants treated in 300 mg-Q4W dose escalation and expansion cohorts, respectively. Phase II: grade 3 TRAEs occurred in 3/41 (7.3%) and 3/80 (3.8%) participants treated with 300 mg-Q4W and 600 mg-Q6W, respectively; no grade 4/5 TRAEs. Phase II: confirmed objective response was observed in 11/41 (26.8% (95% CI, 14.2–42.9)) and 12/80 (15.0% (95% CI, 8.0–24.7)) participants treated with 300 mg-Q4W and 600 mg-Q6W, respectively. Conclusions: Phase Ib regimens were considered safe with no DLTs reported. In phase II, 600 mg-Q6W regimen criteria were met for AUC tau and C trough metrics to support PK-based extrapolation of efficacy of alternative regimen. Regimens were well tolerated, showing anti-tumor activity in participants with advanced solid tumors. Administration of sasanlimab at a dose of 600 mg-Q6W subcutaneously may serve as a convenient alternative to 300 mg-Q4W administration. Trial registration: NCT04181788 (ClinicalTrials.gov); 2019-003818-14 (EudraCT). more...
- Published
- 2024
- Full Text
- View/download PDF
6. Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study
- Author
-
Jiyun Lee, Hee Kyung Ahn, Sang‐We Kim, Ji‐Youn Han, Sung Sook Lee, Hyung Soon Park, Hyun Woo Lee, Joo‐Hang Kim, Eunhan Cho, Reto Huggenberger, and Byoung Chul Cho
- Subjects
chemoradiation ,palliative therapy ,stage III NSCLC ,surgery ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Objective KINDLE‐Korea is part of a real‐world KINDLE study that aimed to characterize the treatment patterns and clinical outcomes of patients with stage III non‐small cell lung cancer (NSCLC). Materials and Methods The KINDLE was an international real‐world study that explores patient and disease characteristics, treatment patterns, and survival outcomes. The KINDLE‐Korea included stage III NSCLC patients diagnosed between January 2013 and December 2017. Results A total of 461 patients were enrolled. The median age was 66 years (range: 24–87). Most patients were men (75.7%) with a history of smoking (74.0%), stage IIIA NSCLC (69.2%), and unresectable disease (52.9%). A total of 24.3% had activating EGFR mutation and 62.2% were positive for PDL1 expression. Broadly categorized, 44.6% of the patients received chemoradiation (CRT)‐based therapy, 35.1% underwent surgery, and 20.3% received palliative therapies as initial treatment. The most commonly adopted approaches for patients with stage IIIA and IIIB disease were surgery and CRT, respectively. The median PFS was 15.2 months and OS was 66.7 months. Age >65 years, adenocarcinoma histology, and surgery as the initial treatment were significantly associated with longer OS. Conclusion This study revealed the heterogeneity of treatment patterns and survival outcomes in patients with stage III NSCLC before durvalumab consolidation came into clinical practice. There is an unmet need for patients who are not eligible for surgery as an initial therapy. Novel therapeutic approaches are highly warranted to improve clinical outcomes. more...
- Published
- 2024
- Full Text
- View/download PDF
7. A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15)
- Author
-
Sun Kyung Baek, Jae-ho Jeong, KyungHae Jung, Hee Kyung Ahn, Min Hwan Kim, Joohyuk Sohn, In Hae Park, Jin Seok Ahn, Dae-Won Lee, Seock-Ah Im, Sung Hoon Sim, Keun Seok Lee, Jee Hyun Kim, Hyun-Jeong Shim, Yeesoo Chae, Su-Jin Koh, Hyorak Lee, Jieun Lee, Jae-Ho Byun, Youngmi Seol, Eun Mi Lee, Hee-Jung Jee, Hyonggin An, Eun Byeol Park, Young Ju Suh, Kyoung Eun Lee, and Yeon Hee Park more...
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Purpose: This study aimed to investigate clinical practices and factors related to the outcomes of T-DM1 use in patients with HER2-positive metastatic breast cancer (mBC). Methods: We included patients with HER2-positive mBC who received T-DM1 as a palliative therapy between August 2017 and December 2018. The safety and outcomes of T-DM1, including overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), were evaluated. A Cox proportional hazards model was used to estimate the hazard ratio and 95% confidence interval (CI) for mortality or progression to HER2-positive mBC. Results: In total, 824 patients were enrolled during the study period. The mean age of patients was 58 years, and 516 (62.6%) patients relapsed after curative treatment. Excluding a history of endocrine therapy, 341 (41.4%) patients previously received none or first-line chemotherapy, 179 (21.7%) received second-line therapy, and 303 (36.9%) received third-or later-line chemotherapy before T-DM1 therapy. During a median follow-up of 16.8 months, the ORR was 35%, the median PFS was 6.6 months, and the median OS was not reached. The clinical factors associated with the hazard of progression were age ( more...
- Published
- 2024
- Full Text
- View/download PDF
8. Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
- Author
-
Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Koung Jin Suh, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, Jae Ho Byun, Jin Hyun Park, Gyeong-Won Lee, Keun Seok Lee, Joohyuk Sohn, Kyung Hae Jung, and In Hae Park more...
- Subjects
Receptor, ErbB-2 ,Physicians ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Breast Neoplasms ,Dioxolanes ,Female ,Surgery ,General Medicine ,Trastuzumab ,Biosimilar Pharmaceuticals - Abstract
We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies. more...
- Published
- 2022
- Full Text
- View/download PDF
9. Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22
- Author
-
Hyun Ae Jung, Min Hee Hong, Hyun Woo Lee, Kyung Hee Lee, Il Hwan Kim, Young Joo Min, Hee Kyung Ahn, Byoung Yong Shim, Yoon Hee Choi, Yun-Gyoo Lee, Jeong A Kim, Joung Soon Jang, Seong-Hoon Shin, Keon Uk Park, Jin Hyoung Kang, and Keunchil Park more...
- Subjects
Oncology - Published
- 2022
- Full Text
- View/download PDF
10. A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial.
- Author
-
Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, Yun-Gyoo Lee, Keun-Wook Lee, Myung-Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, and Jin-Soo Kim
- Subjects
SQUAMOUS cell carcinoma ,FIBROBLAST growth factor receptors - Abstract
Purpose Precision oncology approach for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) is necessary due to its dismal prognosis. We performed a genomic profile-based umbrella trial of patients with platinum-refractory HNSCC (KCSGTRIUMPH). Here, we present an in-depth report of the the nintedanib arm (arm 3) of the current trial. Materials and Methods The TRIUMPH study was a multicenter, open-label, single-arm phase 2 trial, in which patients were assigned to treatment arms based on next-generation sequencing (NGS)-based, matching genomic profiles. Patients whose tumors harbor fibroblast growth factor receptor (FGFR) alteration were enrolled in the nintedanib arm (arm 3) as part of the TRIUMPH study. The primary endpoint was the overall response rate (ORR), and secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, and biomarker analysis. Results Between October 2017 and August 2020, 207 were enrolled in the TRIUMPH study, and eight were enrolled in the nintedanib arm. ORR and disease control rate were 42.9% and 57.1%, respectively. The median PFS was 5.6 months and the median duration of response was 9.1 months. Median OS was 11.1 months. One patient maintained the partial response for 36 months. Overall, the toxicity profiles were manageable. Conclusion Single-agent nintedanib has demonstrated significant efficacy in FGFR-mutated, recurrent or metastatic HNSCC patients, with tolerable toxicity profiles. The results from the study have provided the basis for routine NGS screening and FGFR-targeted therapy. Because of the small number of patients due to slow accrual in this study, further studies with a larger cohort are warranted for statistical power. [ABSTRACT FROM AUTHOR] more...
- Published
- 2024
- Full Text
- View/download PDF
11. Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer
- Author
-
Ho Jung An, Hyun Jeong Jeon, Sang Hoon Chun, Hyun Ae Jung, Hee Kyung Ahn, Kyung Hee Lee, Min-ho Kim, Ju Hee Kim, Jaekyung Cheon, and Su-Jin Koh
- Subjects
Male ,Advance Care Planning ,Terminal Care ,Hospice Care ,Oncology ,Neoplasms ,Humans ,Prospective Studies ,Advance Directives ,Child ,Resuscitation Orders - Abstract
A multicenter prospective study to evaluate the feasibility of Physician Orders for Life-Sustaining Treatment (POLST) in oncology practice was conducted between June and December 2017. Factors associated with POLST completion and follow-up outcomes were analyzed.Patients with terminal cancer, aged ≥ 20 years and capable of communicating, were enrolled from seven hospitals. Demographic data were collected and updated in February 2021. Descriptive statistics and logistic regression analyses were conducted.Among 336 patients, 105 (31.3%) completed POLST, which was more common in male (p = 0.029), patients with better performance (p 0.001), longer duration of follow-up (p = 0.037), and those living with children (p = 0.023). Male (odds ratio [OR], 2.30; 95% confidence interval [CI], 1.17-3.51; p = 0.012), having good performance status (OR, 2.38; 95% CI, (1.35-4.19); p = 0.003), transferred from other departments (OR, 0.50; 95% CI, (0.26-0.98); p = 0.045), and living with children (OR, 1.94; 95% CI, (1.11-3.47); p = 0.020) were significant predictors of POLST completion. Patients who completed POLST were more likely to enroll in hospice care (p = 0.012) or experience out-of-hospital death (p = 0.016) at end-of-life (EOL). POLST completion showed a strong association with hospice enrollment at EOL (OR, 2.61; 95% CI, (1.08-6.32); p = 0.033).Gender, patient performance, timing of POLST discussion, and type of household were associated with POLST completion. Earlier discussions on POLST could reinforce hospice enrollment or non-aggressive EOL care. more...
- Published
- 2022
- Full Text
- View/download PDF
12. Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
- Author
-
Soohyeon Lee, Kyunghee Park, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Hee Kyung Ahn, Woong-Yang Park, Seock-Ah Im, and Yeon Hee Park
- Subjects
DNA Copy Number Variations ,Pyridines ,Receptor, ErbB-2 ,Progression-free survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Breast Neoplasms ,Palbociclib ,Biomarker ,General Medicine ,Hormones ,Piperazines ,Receptors, Estrogen ,Antineoplastic Combined Chemotherapy Protocols ,Next-generation sequencing ,Humans ,Female ,Surgery ,neoplasms ,RC254-282 - Abstract
Background: Palbociclib plus endocrine therapy (ET) demonstrated significant progression-free survival (PFS) benefit in Young Pearl, a randomized phase ll trial comparing palbociclib + ET versus capecitabine in premenopausal women with hormone receptor positive, HER2 negative metastatic breast cancer (MBC). This exploratory analysis investigated potential biomarkers of palbociclib plus ET on PFS. Patients and methods: Of 178 patients randomized (92 palbociclib plus ET; 86 capecitabine), we performed targeted sequencing (141 patients) and whole transcriptome sequencing (165 patients) using baseline tumor samples to examine genomic alteration in relation to drug response on PFS. Hazard ratios (HRs) were estimated using unstratified Cox proportional hazards models. Results: PIK3CA (41%) and TP53 (33%) mutations and CCND1 copy number variation (29%) were found most frequently in targeted sequencing of 141 patients. ESR1 mutations were found only in 3.5% of patients of this population. Luminal type showed better prognosis in palbociclib + ET arm but no impact on PFS difference in capecitabine arm. High TMB, TP53 mutation, PTEN loss of function mutation and RB1 pathway alteration showed worse prognosis in palbociclib plus ET arm. Patients with BRCA2 pathogenic mutations showed worse prognosis regardless of PAM50 subtypes. AURKA mutation/amplification, BRIP1/MYC/RAD51C amplification were significantly associated to the patients with short PFS more...
- Published
- 2022
- Full Text
- View/download PDF
13. ERRATUM: Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
- Author
-
Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se Jin Jang, Dae Young Zang, Tae Won Kim, Jin Hyoung Kang, and Jee Hyun Kim more...
- Subjects
Cancer Research ,Oncology - Published
- 2023
- Full Text
- View/download PDF
14. A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
- Author
-
Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn, So Yeon Oh, Kyung Hee Lee, Su-Jin Koh, Keun Seok Lee, Chan-Kyu Kim, Ji-Yeon Kim, Jun Ho Ji, Sung-Bae Kim, Joo Young Ha, and Ho Young Kim more...
- Subjects
Cancer Research ,Oncology - Published
- 2023
- Full Text
- View/download PDF
15. Abstract P1-18-32: A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG BR19-15)
- Author
-
Sun Kyung Baek, Jae-Ho Jeong, Yeon-Hee Park, Hee Kyung Ahn, Min Hwan Kim, In Hae Park, Young Ju Suh, Dae-Won Lee, Sung Hoon Sim, Jee Hyun Kim, Hyun-Jeong Shim, Yeesoo Chae, Su-Jin Koh, Hyorak Lee, Jieun Lee, Jae-Ho Byun, Youngmi Seol, Eun Mi Lee, Jin Seok Ahn, Kyung-Hae Jung, Seock-Ah Im, Keun Seok Lee, Joohyuk Sohn, and Kyoung Eun Lee more...
- Subjects
Cancer Research ,Oncology - Abstract
Purpose: T-DM1, an antibody-drug conjugate, has significant antitumor activity in patients with HER2-positive metastatic breast cancer (mBC) patients who had progressed after trastuzumab-based chemotherapy. This study was conducted to investigate the clinical practice and factors related with outcomes of T-DM1 use for HER2-positive mBC patients in the nation-wide real-world setting. Method: This complete enumeration study included the patients with HER2-positive mBC who received T-DM1 as palliative therapy from August 2017 to December 2018 under the registry of Health Insurance Review & Assessment Service in Korea. Safety and outcomes of T-DM1 including overall response rate (ORR), progression-free survival (PFS), and overall survival were evaluated. Factors significant in univariate analysis were analyzed in multivariate model. Result: From the sixty institutions, a total of 824 patients were enrolled. Mean age was 58 years-old, 818 patients (99.3%) were female and 516 patients (62.6%) had relapsed after curative treatment. About 40% patients received T-DM1 as first or second line treatment, 21.5% received it as third line and 37.3% as fourth or over line. During a median follow-up of 16.8 months, the ORR was 32.8%, median PFS was 7.2 months and median OS was not reached. In multivariate analysis, clinical factors associated with the lower PFS were age (< 65 year-old, hazard ratio[HR] 1.53, 95% confidence interval[CI]: 1.214-1.919, p < 0.001), poor ECOG performance status (PS ≥ 2, HR 1.98, 95% CI: 1.493-2.626, p < 0.001), previous pertuzumab use (HR 1.40, 95% CI: 1.118-1.742, p = 0.003) and previous lapatinib use (HR 1.29, 95% CI: 1.047-1.586, p =0.017). The common grade 3-4 adverse events were thrombocytopenia (13.0%), neutropenia (2.9%), and elevation of liver enzyme (2.5%). Hypokalemia (≤ 3.0 mmol/L) and any-grade bleeding event such as epistaxis and gum-bleeding occurred in 25 (3.1%) and 94 patients (11.4%), respectively. Conclusion: This is the first, nationwide, real-world data about T-DM1 use of the HER2-positive metastatic breast cancer patients in Korea. The efficacy and toxicity profile of T-DM1 in the real-world practice were comparable with those of randomized trials. Patients’ factors and previous anti-HER2 therapy could predict the outcomes of T-DM1. Further studies to reveal the subtypes of good responders to T-DM1 and the sequence of anti-HER2 therapy are warranted. Citation Format: Sun Kyung Baek, Jae-Ho Jeong, Yeon-Hee Park, Hee Kyung Ahn, Min Hwan Kim, In Hae Park, Young Ju Suh, Dae-Won Lee, Sung Hoon Sim, Jee Hyun Kim, Hyun-Jeong Shim, Yeesoo Chae, Su-Jin Koh, Hyorak Lee, Jieun Lee, Jae-Ho Byun, Youngmi Seol, Eun Mi Lee, Jin Seok Ahn, Kyung-Hae Jung, Seock-Ah Im, Keun Seok Lee, Joohyuk Sohn, Kyoung Eun Lee. A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG BR19-15) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-18-32. more...
- Published
- 2022
- Full Text
- View/download PDF
16. Abstract P5-16-03: Phase II study of trastuzumab biosimilar (Herzuma®) plus gedatolisib in patients with HER-2 positive metastatic breast cancer who progressed after 2 or more HER-2 directed chemotherapy (BR 18-13, KM-10A): Interim analysis
- Author
-
Ju Won Kim, Hee Kyung Ahn, Jong Gwon Choi, Yee Soo Chae, Gyeong-Won Lee, Keon Uk Park, Eunmi Lee, Sung Hoon Sim, Jee Hyun Kim, Yeon Hee Park, Miso Kim, Jin Hyun Park, Jeong Eun Kim, Han Jo Kim, Mi Sun Ahn, So Yeon Oh, Min Hwan Kim, Su-Jin Koh, Kyoung Eun Lee, Myoung Joo Kang, Jae Ho Byun, Joo Young Ha, Jung Hye Kwon, Joo Young Jung, Su Ee Lee, Inhae Park, and Kyong Hwa Park more...
- Subjects
Cancer Research ,Oncology - Abstract
Background: Prognosis of patients with HER-2 positive metastatic breast cancer (MBC) has been revolutionized with the development of monoclonal antibodies targeting HER-2 and antibody-drug conjugate, but resistance to anti-HER-2 therapy is inevitable ultimately. PI3K-AKT-mTOR pathway aberration is known to be one of the key resistance mechanisms. BR18-13(KM-10A) study is a phase 2 clinical trial evaluating efficacy and safety of Herzuma® (trastuzumab biosimilar) plus Gedatolisib (dual PI3K/mTORC inhibitor) in patients with HER-2 positive MBC who progressed after multiple lines of therapy. Methods: Patients with HER-2 positive MBC with known PIK3CA pathologic mutation or amplification whose disease progressed after more than 2 HER-2 directed therapy were enrolled in the study. They received Herzuma® (8mg/kg IV for 1st cycle loading dose, and then 6mg/kg IV every 3 weeks) plus Gedatolisib (180mg on D1, 8, 15 of every 21 days). We evaluated efficacy of the combination treatment as interim analysis. The data cutoff of this interim analysis was June 8, 2021. Results: 17 patients were enrolled and followed for a median of 6.2 months. At data cutoff, 17 patients were eligible for response assessment. All patients were confirmed to have pathologic PIK3CA aberrations: 9 kinase mutations (H1047X), 5 helical mutations (E545X), 2 other point mutations, and 1 amplification. Overall, response rate was 64.7% and disease control rate was 82.4%. Eleven patients reached partial response (PR) as their best response, three were stable disease (SD), and three had progressive disease (PD). Two patients who have reached PR remain on investigational treatment until the data cutoff point, and the longest one is on treatment for 12.0 months. The median progression-free survival assessed in data cutoff time was 5.9 months. One patient ended treatment due to CNS disease progression, but her visceral metastatic lesions were decreased with experimental treatment. No fatal adverse events related to trial medication were reported. Conclusion: In this phase 2 study, Trastuzumab biosimilar plus Gedatolisib presented 64.7% of response rate with manageable toxicity in patients with HER-2 positive MBC with PIK3CA mutation. Clinical trial information: NCT03698383 Acknowledgement: this research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &Welfare, Republic of Korea (Grant number: HI17C2206). Citation Format: Ju Won Kim, Hee Kyung Ahn, Jong Gwon Choi, Yee Soo Chae, Gyeong-Won Lee, Keon Uk Park, Eunmi Lee, Sung Hoon Sim, Jee Hyun Kim, Yeon Hee Park, Miso Kim, Jin Hyun Park, Jeong Eun Kim, Han Jo Kim, Mi Sun Ahn, So Yeon Oh, Min Hwan Kim, Su-Jin Koh, Kyoung Eun Lee, Myoung Joo Kang, Jae Ho Byun, Joo Young Ha, Jung Hye Kwon, Joo Young Jung, Su Ee Lee, Inhae Park, Kyong Hwa Park. Phase II study of trastuzumab biosimilar (Herzuma®) plus gedatolisib in patients with HER-2 positive metastatic breast cancer who progressed after 2 or more HER-2 directed chemotherapy (BR 18-13, KM-10A): Interim analysis [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-16-03. more...
- Published
- 2022
- Full Text
- View/download PDF
17. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer
- Author
-
Joo-Hwan Park, Ja Hyun Yeo, Young Saing Kim, Inkeun Park, Hee Kyung Ahn, Eun Kyung Cho, Dong Bok Shin, Jun-Young Yang, Hyung-Sik Kim, Woon Kee Lee, and Sun Jin Sym
- Subjects
Cancer Research ,Oncology - Published
- 2022
- Full Text
- View/download PDF
18. Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)
- Author
-
Bhumsuk Keam, Keon Uk Park, Hye Ryun Kim, Keun-Wook Lee, Sung-Bae Kim, Seong Hoon Shin, Jin-Hyuk Choi, Eun Joo Kang, Yun-Gyoo Lee, Hyo Jung Kim, Min Kyoung Kim, Hwan Jung Yun, Kyoung Eun Lee, Jin-Soo Kim, and Hee Kyung Ahn more...
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Locally advanced ,Docetaxel ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Risk of mortality ,medicine ,Humans ,Subsequent treatment ,Locally advanced head and neck squamous cell carcinoma ,Survival rate ,Aged ,Retrospective Studies ,Squamous Cell Carcinoma of Head and Neck ,business.industry ,Head and Neck cancer ,Hazard ratio ,Induction chemotherapy ,Induction Chemotherapy ,Middle Aged ,medicine.disease ,Head and neck squamous-cell carcinoma ,Confidence interval ,030104 developmental biology ,Drug Resistance, Neoplasm ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Cohort ,Female ,Original Article ,Fluorouracil ,Cisplatin ,business ,Follow-Up Studies - Abstract
Purpose Certain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of IC in guiding the selection of a definitive locoregional therapy.Materials and Methods Out of the 445 patients in multi-institutional LA-HNSCC cohort, 158 (36%) receiving IC were enrolled. The study outcome was to assess overall survival (OS) through IC responsiveness and its role to select subsequent treatments.Results Among 135 patients who completed subsequent treatment following IC, 74% responded to IC (complete response in 17% and partial response in 58%). IC-non-responders showed 4.5 times higher risk of mortality than IC-responders (hazard ratio, 4.52; 95% confidence interval, 2.32 to 8.81; p < 0.001). Among IC-responders, 84% subsequently received definitive concurrent chemoradiotherapy (CCRT) and OS was not differed by surgery or CCRT (p=0.960). Regarding IC-non-responders, 54% received CCRT and 46% underwent surgery, and OS was poor in CCRT (24-month survival rate of 38%) or surgery (24-month survival rate of 63%).Conclusion Response to IC is a favorable prognostic factor. For IC-responders, either surgery or CCRT achieved similar survival probabilities. For IC-non-responder, multidisciplinary approach was warranted reflecting patients’ preference, morbidity, and prognosis. more...
- Published
- 2022
- Full Text
- View/download PDF
19. Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)
- Author
-
Eun Joo Kang, Yun-Gyoo Lee, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Hyo Jung Kim, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Jii Bum Lee, Jung Hye Kwon, Hye Ryun Kim, Sung-Bae Kim, and Hwan Jung Yun more...
- Subjects
Squamous Cell Carcinoma of Head and Neck ,Chemoradiotherapy ,Hemato-Oncology ,aged ,head and neck neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,therapeutics ,Humans ,Medicine ,Original Article ,Fluorouracil ,Cisplatin ,Retrospective Studies - Abstract
Background/Aims: Treatment decisions for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) are complicated, and multi-modal treatments are usually indicated. However, it is challenging for older patients to complete treatments. Thus, we investigated disease characteristics, real-world treatment, and outcomes in older LA-HNSCC patients.Methods: Older patients (aged ≥ 70 years) were selected from a large nationwide cohort that included 445 patients with stage III–IVB LA-HNSCC from January 2005 to December 2015. Their data were retrospectively analyzed and compared with those of younger patients.Results: Older patients accounted for 18.7% (83/445) of all patients with median age was 73 years (range, 70 to 89). Proportions of primary tumors in the hypopharynx and larynx were higher in older patients and older patients had a more advanced T stage and worse performance status. Regarding treatment strategies of older patients, 44.5% of patients received concurrent chemoradiotherapy (CCRT), 41.0% underwent surgery, and 14.5% did not complete the planned treatment. Induction chemotherapy (IC) was administered to 27.7% (23/83) of older patients; the preferred regimen for IC was fluorouracil and cisplatin (47.9%). For CCRT, weekly cisplatin was prescribed 3.3 times more often than 3-weekly cisplatin (62.2% vs. 18.9%). Older patients had a 60% higher risk of death than younger patients (hazard ratio, 1.6; p = 0.035). Oral cavity cancer patients had the worst survival probability.Conclusions: Older LA-HNSCC patients had aggressive tumor characteristics and received less intensive treatment, resulting in poor survival. Further research focusing on the older population is necessary. more...
- Published
- 2022
20. Blue native-PAGE of protein complexes in plant cells v1
- Author
-
Hee-Kyung Ahn
- Abstract
Many protein complexes exist in cells, and these protein complexes are vital for cellular processes. However, much of our current analyses of protein-protein interaction mainly focus on binary interactions. Non-denaturing PAGE (polyacrylamide gel electrophoresis) provides an efficient method that enables analysis of multimeric protein complexes in vivo. In contrast to chromatography or sucrose fractionation methods, small amount of sample is required for analysis, and multiple combinations of samples can be tested simultaneously. Non-denaturing PAGE using the Coomassie G-250 dye, also known as blue native-PAGE resolves protein complexes according to their molecular weight and has been successfully used to identify protein complexes bound to membranes such as in mitochondria and chloroplasts. Recently, intracellular immune receptors in plants localizing in the cytoplasm, nucleus or plasma membrane were analyzed using the blue-native PAGE method. Here we share our method of resolving protein complexes from plant extracts or immunoprecipitated samples from plant cells on blue native-PAGE. more...
- Published
- 2023
- Full Text
- View/download PDF
21. Knowledge, attitudes, and behaviors toward fertility preservation in patients with breast cancer: A cross-sectional survey of physicians
- Author
-
Soo Yeon Baek, Kyung-Hun Lee, Sung-Bae Kim, Henry Gomez, Tatiana Vidaurre, Yeon Hee Park, Hee Kyung Ahn, Yoo Seok Kim, In Hae Park, Sung Gwe Ahn, Jeeyeon Lee, Jae Ho Jeong, Seonok Kim, and Hee Jeong Kim more...
- Subjects
Cancer Research ,Oncology - Abstract
BackgroundFertility is an important issue for young women with breast cancer, but studies about physicians’ knowledge, attitudes, and practices toward fertility preservation (FP) are largely based on Western populations and do not reflect recent international guidelines for FP. In this international study, we aimed to assess the knowledge, attitudes, and practices of physicians from South Korea, other Asian countries, and Latin America toward FP in young women with breast cancer, and identify the related barriers.MethodsThe survey was conducted anonymously among physicians from South Korea, other Asian countries, and Latin America involved in breast cancer care between November 2020 and July 2021. Topics included knowledge, attitudes, and perceptions toward FP; practice behaviors; barriers; and participant demographics. We grouped related questions around two main themes—discussion with patients about FP, and consultation and referral to a reproductive endocrinologist. We analyzed the relationships between main questions and other survey items.ResultsA total of 151 physicians completed the survey. Most participants’ overall knowledge about FP was good. More than half of the participants answered that they discussed FP with their patients in most cases, but that personnel to facilitate discussions about FP and the provision of educational materials were limited. A major barrier was time constraints in the clinic (52.6%). Discussion, consultations, and referrals were more likely to be performed by surgeons who primarily treated patients with operable breast cancer (FP discussion odds ratio [OR]: 2.90; 95% confidence interval [CI]: 1.24–6.79; FP consultation and referral OR: 2.98; 95% CI: 1.14–7.74). Participants’ knowledge and attitudes about FP were significantly associated with discussion, consultations, and referrals.ConclusionPhysicians from South Korea, other Asian countries, and Latin America are knowledgeable about FP and most perform practice behaviors toward FP well. Physicians’ knowledge and favorable attitudes are significantly related to discussion with patients, as well as consultation with and referral to reproductive endocrinologists. However, there are also barriers, such as limitations to human resources and materials, suggesting a need for a systematic approach to improve FP for young women with breast cancer. more...
- Published
- 2023
- Full Text
- View/download PDF
22. Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01)
- Author
-
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hyo Jung Kim, and Hwan Jung Yun more...
- Subjects
Cancer Research ,Oncology ,locally advanced head and neck squamous cell carcinoma ,gender ,clinical outcome - Abstract
We aimed to compare treatment modalities and outcomes by gender in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). We characterized the sex-specific differences and compared the overall survival (OS) between male and female patients in a multicenter cohort of LA-HNSCC. To minimize the observed confounding, propensity score matching was utilized. The study included 445 patients; 385 (86.5%) were men and 60 (13.5%) were women. In terms of age, smoking habits, drinking habits, and primary tumor locations, there was a significant imbalance in sex before the matching. Propensity score matching yielded 60 patient pairs, with no statistical difference between the sexes in terms of their characteristics. As for the treatment strategies, there were no significant differences between the sexes before (p = 0.260) and after (p = 0.585) the propensity score matching. When comparing the survival probabilities between the sexes, OS was not significantly different in the overall (HR 1.02; 95% CI 0.59–1.76; p = 0.938) and propensity-score-matched population (HR 1.46; 95% CI 0.68–3.17; p = 0.331). These results suggest that there was no difference in prognosis by gender in the treatment modalities and outcomes of LA-HNSCC in real-world practice. more...
- Published
- 2023
- Full Text
- View/download PDF
23. Effector‐dependent activation and oligomerization of plant <scp>NRC</scp> class helper <scp>NLRs</scp> by sensor <scp>NLR</scp> immune receptors Rpi‐amr3 and Rpi‐amr1
- Author
-
Hee‐Kyung Ahn, Xiao Lin, Andrea Carolina Olave‐Achury, Lida Derevnina, Mauricio P Contreras, Jiorgos Kourelis, Chih‐Hang Wu, Sophien Kamoun, and Jonathan D G Jones
- Subjects
General Immunology and Microbiology ,General Neuroscience ,Molecular Biology ,General Biochemistry, Genetics and Molecular Biology - Abstract
Plant pathogens compromise crop yields. Plants have evolved robust innate immunity that depends in part on intracellular Nucleotide-binding, Leucine rich-Repeat (NLR) immune receptors that activate defense responses upon detection of pathogen-derived effectors. Most "sensor" NLRs that detect effectors require the activity of "helper" NLRs, but how helper NLRs support sensor NLR function is poorly understood. Many Solanaceae NLRs require NRC (NLR-Required for Cell death) class of helper NLRs. We show here that Rpi-amr3, a sensor NLR from Solanum americanum, detects AVRamr3 from the potato late blight pathogen, Phytophthora infestans, and activates oligomerization of helper NLRs NRC2 and NRC4 into high-molecular-weight resistosomes. In contrast, recognition of P. infestans effector AVRamr1 by another sensor NLR Rpi-amr1 induces formation of only the NRC2 resistosome. The activated NRC2 oligomer becomes enriched in membrane fractions. ATP-binding motifs of both Rpi-amr3 and NRC2 are required for NRC2 resistosome formation, but not for the interaction of Rpi-amr3 with its cognate effector. NRC2 resistosome can be activated by Rpi-amr3 upon detection of AVRamr3 homologs from other Phytophthora species. Mechanistic understanding of NRC resistosome formation will underpin engineering crops with durable disease resistance. more...
- Published
- 2023
- Full Text
- View/download PDF
24. Characteristics Associated with Survival in Patients Receiving Continuous Deep Sedation in a Hospice Care Unit
- Author
-
Hee Kyung Ahn, Hong Yup Ahn, So Jung Park, and In Cheol Hwang
- Published
- 2021
- Full Text
- View/download PDF
25. Awareness of Doctors’ Shared Decision-Making in Life-Sustaining Care Decisions
- Author
-
Dalyong Kim, Hyun Jung Lee, Soo-Young Yu, Jung Hye Kwon, Hee Kyung Ahn, Jee Hyun Kim, Seyoung Seo, Chi Hoon Maeng, Seungtaek Lim, Do Yeun Kim, and Sung Joon Shin
- Published
- 2021
- Full Text
- View/download PDF
26. Recent Treatment Patterns of Oropharyngeal Cancer in Korea Based on the Expert Questionnaire Survey of the Korean Society for Head and Neck Oncology (KSHNO)
- Author
-
Jeongshim Lee, Yeon-Sil Kim, Inn-Chul Nam, Woo Jin Jeong, Kye Hye Choi, Young Hoon Joo, Sang Hoon Chun, Young Gyu Eun, Ji Hoon Kim, Hee Kyung Ahn, Sung Ho Moon, Jin Ho Kim, Jin Ho Song, and Hyun Jun Hong more...
- Subjects
Male ,0301 basic medicine ,Human papillomavirus ,Cancer Research ,medicine.medical_specialty ,Oropharyngeal neoploasms ,Specialty ,03 medical and health sciences ,0302 clinical medicine ,Robotic Surgical Procedures ,Surveys and Questionnaires ,Republic of Korea ,Humans ,Medicine ,Practice Patterns, Physicians' ,Stage (cooking) ,Papillomaviridae ,Treatment patterns ,Aged ,business.industry ,General surgery ,Incidence (epidemiology) ,Papillomavirus Infections ,Induction chemotherapy ,Cancer ,Questionnaire ,Chemoradiotherapy ,Middle Aged ,Prognosis ,medicine.disease ,Head and Neck Cancer ,Combined Modality Therapy ,Oropharyngeal Neoplasms ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Questionnaire study ,Carcinoma, Squamous Cell ,Head and neck oncology ,Original Article ,Female ,business ,Follow-Up Studies - Abstract
Purpose The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has increased, and staging and optimal therapeutic approaches are challenging. A questionnaire survey was conducted to investigate the controversial treatment policy of stage T2 OPC according to the N category and determine the opinions of multidisciplinary experts in Korea.Materials and Methods Five OPC scenarios were developed by the Subcommittee on Oropharyngeal Treatment Guidelines of the Korean Society for Head and Neck Oncology and distributed to experts of multidisciplinary treatment hospitals.Results Sixty-five experts from 45 institutions responded. For the HPV-positive T2N0M0 scenario, 67.7% of respondents selected surgery followed by definitive concurrent chemoradiotherapy (CCRT) or radiotherapy alone. For the T2N1M0 HPV-positive scenario, there was a notable difference in the selection of primary treatment by expert specialty; 53.9% of respondents selected surgery and 39.8% selected definitive CCRT as the primary treatment. For the T2N3M0 advanced HPV-positive scenario, 50.0% of respondents selected CCRT and 33.3% considered induction chemotherapy (IC) as the primary treatment. CCRT and IC were significantly more frequently selected for the HPV-related OPC cases (p=0.010). The interdepartmental variability showed that the head and neck surgeons and medical oncologists favored surgery, whereas the radiation oncologists preferably selected definitive CCRT (p < 0.001).Conclusion In this study, surgery was preferred for lymph node-negative OPC, and as lymph node metastasis progressed, CCRT tended to be preferred, and IC was administered. Clinical practice patterns by stage and HPV status showed differences according to expert specialty. Multidisciplinary consensus guidelines will be essential in the future. more...
- Published
- 2021
- Full Text
- View/download PDF
27. Sensor <scp>NLR</scp> immune proteins activate oligomerization of their <scp>NRC</scp> helpers in response to plant pathogens
- Author
-
Mauricio P Contreras, Hsuan Pai, Yasin Tumtas, Cian Duggan, Enoch Lok Him Yuen, Angel Vergara Cruces, Jiorgos Kourelis, Hee‐Kyung Ahn, Kim‐Teng Lee, Chih‐Hang Wu, Tolga O Bozkurt, Lida Derevnina, and Sophien Kamoun more...
- Subjects
General Immunology and Microbiology ,General Neuroscience ,Molecular Biology ,General Biochemistry, Genetics and Molecular Biology - Abstract
Nucleotide-binding domain leucine-rich repeat (NLR) immune receptors are important components of plant and metazoan innate immunity that can function as individual units or as pairs or networks. Upon activation, NLRs form multiprotein complexes termed resistosomes or inflammasomes. Although metazoan paired NLRs, such as NAIP/NLRC4, form hetero-complexes upon activation, the molecular mechanisms underpinning activation of plant paired NLRs, especially whether they associate in resistosome hetero-complexes, is unknown. In asterid plant species, the NLR required for cell death (NRC) immune receptor network is composed of multiple resistance protein sensors and downstream helpers that confer immunity against diverse plant pathogens. Here, we show that pathogen effector-activation of the NLR proteins Rx (confers virus resistance), and Bs2 (confers bacterial resistance) leads to oligomerization of their helper NLR, NRC2. Activated Rx does not oligomerize or enter into a stable complex with the NRC2 oligomer and remains cytoplasmic. In contrast, activated NRC2 oligomers accumulate in membrane-associated puncta. We propose an activation-and-release model for NLRs in the NRC immune receptor network. This points to a distinct activation model compared with mammalian paired NLRs. more...
- Published
- 2022
- Full Text
- View/download PDF
28. Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea
- Author
-
Cliff Molife, Jae Min Cho, Jennifer Lapthorn, Min Ju Kang, Yulia D’yachkova, Sangmi Kim, Sam Colman, Saerom Kim, Agota Szende, Ji Hyun Park, Hee Kyung Ahn, Min Hee Hong, Kaisa-Leena Taipale, and Hye Ryun Kim more...
- Subjects
Pharmacology (medical) - Abstract
Despite the dynamic treatment landscape for EGFR mutant-positive metastatic non-small cell lung cancer (EGFRm+ mNSCLC), most of the earlier studies have focused on US or Western populations.The objective of this study was to explore real-world treatment patterns and outcomes of South Korean patients with EGFRm+ mNSCLC.Retrospective chart review of adult patients with EGFRm+ mNSCLC who received systemic treatment between January-2019 and June-2019.A total of 162 patients were included from 21 hospitals, with a median follow-up of 15.6 months. Median age was 65.0 years, 22% had central nervous system metastasis, and 57% and 38% had exon 19 deletion and exon 21 L858R, respectively. Among 144 patients (89%) who received first-line EGFR-tyrosine kinase inhibitor, afatinib was most the common (44%), followed by gefitinib (28%) and erlotinib (13%). First-line chemotherapy was more common when an EGFR-mutation was detected after versus before first-line treatment initiation (31% vs 5%). Discontinuation of first-line treatment was mostly due to disease-progression (81%) and toxicity (7%). Among 58 (78%) patients who received second-line treatment, osimertinib was the most common (40%). Most (60%) patients reported ≥1 Grade ≥3 adverse event during first-line treatment. Following initiation of first-line treatment, physician visits and chest X-rays were the most frequent healthcare utilisation events. Rates of emergency-room visits and hospitalization were 12% and 16%, respectively, with a mean length-of-stay of 10.4 days. At 12 months, overall survival rate was 95%, and numerically worse for patients with exon 21 versus 19 mutations.Characteristics and clinical outcomes of Korean patients with EGFRm+ mNSCLC in real-world practice were comparable to those observed in clinical trials. As osimertinib was not reimbursed for first-line treatment before study completion, further investigation is warranted to explore evolving treatment practice. more...
- Published
- 2022
29. Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study (Preprint)
- Author
-
Min Jeong Kim, Hyo Jung Kim, Danbee Kang, Hee Kyung Ahn, Soo-Yong Shin, Seri Park, Juhee Cho, and Yeon Hee Park
- Abstract
BACKGROUND In recent decades, real-world evidence (RWE) in oncology has rapidly gained traction for its potential to answer clinical questions that cannot be directly addressed by randomized clinical trials. Integrating real-world data (RWD) into clinical research promises to contribute to more sustainable research designs, including extension, augmentation, enrichment, and pragmatic designs. Nevertheless, clinical research using RWD is still limited because of concerns regarding the shortage of best practices for extracting, harmonizing, and analyzing RWD. In particular, pragmatic screening methods to determine whether the content of a data source is sufficient to answer the research questions before conducting the research with RWD have not yet been established. OBJECTIVE We examined the PAR (Preliminary Attainability Assessment of Real-World Data) framework and assessed its utility in breast cancer brain metastasis (BCBM), which has an unmet medical need for data attainability screening at the preliminary step of observational studies that use RWD. METHODS The PAR framework was proposed to assess data attainability from a particular data source during the early research process. The PAR framework has four sequential stages, starting with clinical question clarification: (1) operational definition of variables, (2) data matching (structural/semantic), (3) data screening and extraction, and (4) data attainability diagramming. We identified 5 clinical questions to be used for PAR framework evaluation through interviews and validated them with a survey of breast cancer experts. We used the Samsung Medical Center Breast Cancer Registry, a hospital-based real-time registry implemented in March 2021, leveraging the institution’s anonymized and deidentified clinical data warehouse platform. The number of breast cancer patients in the registry was 45,129; it covered the period from June 1995 to December 2021. The registry consists of 24 base data marts that represent disease-specific breast cancer characteristics and care pathways. The outcomes included screening results of the clinical questions via the PAR framework and a procedural diagram of data attainability for each research question. RESULTS Data attainability was tested for study feasibility according to the PAR framework with 5 clinical questions for BCBM. We obtained data sets that were sufficient to conduct studies with 4 of 5 clinical questions. The research questions stratified into 3 types when we developed data fields for clearly defined research variables. In the first, only 1 question could be answered using direct data variables. In the second, the other 3 questions required surrogate definitions that combined data variables. In the third, the question turned out to be not feasible for conducting further analysis. CONCLUSIONS The adoption of the PAR framework was associated with more efficient preliminary clinical research using RWD from BCBM. Furthermore, this framework helped accelerate RWE generation through clinical research by enhancing transparency and reproducibility and lowering the entry barrier for clinical researchers. more...
- Published
- 2022
- Full Text
- View/download PDF
30. An updated algorithm for the treatment of spinal metastasis
- Author
-
Kawngwoo Park, Sun Jin Sym, Inkeun Park, Young Saing Kim, Hee Kyung Ahn, Sang Gu Lee, Seong Son, and En Kyung Cho
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,medicine ,Spinal metastasis ,Radiology ,business ,Radiosurgery - Published
- 2021
- Full Text
- View/download PDF
31. You have got items to show off your pride: the effects of pride on preference for attention-grabbing products
- Author
-
Wen Ying Ke, Seung-Hwa Kim, and Hee-Kyung Ahn
- Subjects
Marketing ,Pride ,Emotion classification ,media_common.quotation_subject ,Context (language use) ,Affect (psychology) ,Preference ,Innate intelligence ,Targeted advertising ,Psychology ,Social psychology ,Consumer behaviour ,media_common - Abstract
PurposeThis study examines the impact of incidental pride on consumer preference for attention-grabbing products. This effect is mediated by the desire to gain attention. This study also shows that the effect of incidental pride is qualified by visibility of consumption.Design/methodology/approachUsing two studies with between-subjects designs, this research examines the difference in preferences for attention-grabbing products between hubristic and authentic pride.FindingsIndividuals who experience hubristic pride (vs authentic pride) show greater preference for attention-grabbing products and have a strong desire to gain attention from others. However, when consumption is perceived as private (vs public), preferences for attention-grabbing products weaken for those who experience hubristic pride.Research limitations/implicationsThis research studies the effect of incidental pride on consumer preference. By examining dispositional pride effects, future research may expand these findings, which enrich the literature on emotion. Future research can identify the potential mechanism for the relationship between authentic pride and preference for attention-grabbing products in the context of private consumption.Practical implicationsMarketers and salespersons can guide and recommend products with attention-grabbing features to customers celebrating a friend’s success in recognition of their innate ability. Second, marketers may encourage consumers to buy attention-grabbing products with targeted advertising or emotion-eliciting advertising (i.e., evoke a certain type of pride).Originality/valueWhile prior studies focused on basic emotions, this research has investigated self-conscious emotions that are central to consumer behavior. This research contributes to the understanding of self-conscious emotions that affect consumers’ behavioral responses in unrelated situations. Investigating the two facets of pride, the findings show the impact of pride on the preference for attention-grabbing products and reveals that visibility of consumption moderates the effect of pride. more...
- Published
- 2021
- Full Text
- View/download PDF
32. Longitudinal changes in skeletal muscle mass in patients with advanced squamous cell lung cancer
- Author
-
Sang-Woong Lee, Young Saing Kim, Hee Kyung Ahn, Young Jae Kim, Eun Young Kim, Eunji Kim, Jong Soo Lee, and Kwang Gi Kim
- Subjects
Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,Sarcopenia ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Urology ,chemotherapy ,Squamous cell lung cancer ,03 medical and health sciences ,0302 clinical medicine ,Humans ,Medicine ,In patient ,Longitudinal Studies ,Muscle, Skeletal ,Lung cancer ,RC254-282 ,Aged ,Retrospective Studies ,Chemotherapy ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Skeletal muscle ,Retrospective cohort study ,Original Articles ,General Medicine ,Prognosis ,medicine.disease ,Confidence interval ,lung cancer ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Female ,Original Article ,business ,cancer cachexia - Abstract
Background Skeletal muscle depletion (sarcopenia) is associated with poor prognosis in patients with lung cancer. We analyzed changes in skeletal muscle area using serial computed tomography (CT) until the death of patients with advanced squamous cell lung cancer (SQCLC). Methods This retrospective study comprised 70 consecutive patients who underwent palliative chemotherapy for SQCLC. The cross‐sectional area of the skeletal muscle at the level of the first lumbar vertebra (L1) was measured using chest CT. An artificial intelligence algorithm was developed and used for the serial assessment of the muscle area. Sarcopenia was defined as an L1 skeletal muscle index 3.24 cm2/month) had shorter overall survival than patients losing skeletal muscle slowly (median, 5.7 vs. 12.0 months, p, Patients with advanced SQCLC lose a significant amount of skeletal muscle until death. The rate of muscle area reduction is faster at the end of life. more...
- Published
- 2021
- Full Text
- View/download PDF
33. Fast calculation of subpixel shift for aperture synthesis in digital holographic microscopy
- Author
-
Hwihyeong Lee and Hee Kyung Ahn
- Subjects
General Engineering ,Atomic and Molecular Physics, and Optics - Published
- 2022
- Full Text
- View/download PDF
34. Mutual potentiation of plant immunity by cell-surface and intracellular receptors
- Author
-
Jonathan D. G. Jones, Hee-Kyung Ahn, Pingtao Ding, and Bruno Pok Man Ngou
- Subjects
0106 biological sciences ,0301 basic medicine ,Hypersensitive response ,Programmed cell death ,Plant Immunity ,chemical and pharmacologic phenomena ,01 natural sciences ,03 medical and health sciences ,Immune system ,Immunity ,Arabidopsis ,Receptor ,030304 developmental biology ,0303 health sciences ,Multidisciplinary ,biology ,Chemistry ,Effector ,Long-term potentiation ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,Cell biology ,030104 developmental biology ,bacteria ,Intracellular ,010606 plant biology & botany - Abstract
The plant immune system involves cell-surface receptors that detect intercellular pathogen-derived molecules, and intracellular receptors that activate immunity upon detection of pathogen-secreted effector proteins that act inside the plant cell. Immunity mediated by surface receptors has been extensively studied1, but that mediated by intracellular receptors has rarely been investigated in the absence of surface-receptor-mediated immunity. Furthermore, interactions between these two immune pathways are poorly understood. Here, by activating intracellular receptors without inducing surface-receptor-mediated immunity, we analyse interactions between these two distinct immune systems in Arabidopsis. Pathogen recognition by surface receptors activates multiple protein kinases and NADPH oxidases, and we find that intracellular receptors primarily potentiate the activation of these proteins by increasing their abundance through several mechanisms. Likewise, the hypersensitive response that depends on intracellular receptors is strongly enhanced by the activation of surface receptors. Activation of either immune system alone is insufficient to provide effective resistance against the bacterial pathogen Pseudomonas syringae. Thus, immune pathways activated by cell-surface and intracellular receptors in plants mutually potentiate to activate strong defences against pathogens. These findings reshape our understanding of plant immunity and have broad implications for crop improvement. In Arabidopsis, two distinct types of immunity—that mediated by cell-surface receptors and that mediated by intracellular receptors—interact with and mutually enhance each other to provide effective defence against pathogens. more...
- Published
- 2021
- Full Text
- View/download PDF
35. Abstract PS5-19: Exploratory biomarker analysis of Young-PEARL [palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with HR (hormone receptor)-positive, HER2-negative metastatic breast cancer (MBC)] study
- Author
-
Seock-Ah Im, In Hae Park, Kyunghee Park, Kyung Hae Jung, Seok Yun Kang, Jee Hyun Kim, Yeon Hee Park, Woong-Yang Park, Hee Kyung Ahn, and Gun Min Kim
- Subjects
Agonist ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,engineering.material ,Palbociclib ,medicine.disease ,Metastatic breast cancer ,Capecitabine ,chemistry.chemical_compound ,Exemestane ,chemistry ,Hormone receptor ,Internal medicine ,medicine ,engineering ,Biomarker Analysis ,business ,Pearl ,medicine.drug - Abstract
Background: Young-PEARL study showed median progression-free survival (PFS) of 20·1 months in the palbociclib plus endocrine therapy group versus 14·4 months in the capecitabine group (hazard ratio 0·659 [95% CI 0·437-0·994], log-rank p=0·0235). We conducted exploratory biomarker analysis to predict the efficacy of the trial. Methods: This was a phase II trial that randomized 184 patients with HR+ MBC in premenopausal women to palbociclib plus exemestane with GNRH agonist (Arm A, n=79) versus capecitabine (Arm B, n=62). We performed targeted sequencing (CancerSCANTM) containing 375 cancer-related genes (141 patients) and whole transcriptome sequencing (165 patients) using baseline tumor samples to examine genomic alteration in relation to drug response in terms of PFS. Result: By research-based PAM50 subtyping, 73% of patients classified as Luminal (Luminal A and Luminal B), and showed better prognosis in all patients and Arm A (p Conclusions: The alteration of a few genes including Rb1 loss may be associated with resistance of palbociclib in HR-positive premenopausal population with MBC. Luminal type showed better prognosis, and BRCA2 pathogenic mutation showed worse prognosis regardless luminal/non-luminal type. ESR1 mutation was found in low population frequency because all patients didn’t received AI therapy. Further exploration of molecular variables is warranted to determine and validate biomarkers of efficacy. Clinical trial information: NCT02592746. Citation Format: Kyunghee Park, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Hee Kyung Ahn, Woong-Yang Park, Seock-Ah Im, Yeon Hee Park. Exploratory biomarker analysis of Young-PEARL [palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with HR (hormone receptor)-positive, HER2-negative metastatic breast cancer (MBC)] study [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS5-19. more...
- Published
- 2021
- Full Text
- View/download PDF
36. Abstract PS11-39: Phase II pilot study of trastuzumab biosimilar (herzuma®) plus gedatolisib in patients with HER-2 positive metastatic breast cancer who progressed after 2 or more HER-2 directed chemotherapy [KM-10A/KCSG18-13 interim analysis]
- Author
-
Myoung Joo Kang, Joo Young Jung, Jung Hye Kwon, Sung Hoon Sim, Keon Uk Park, Hee Kyung Ahn, Jeong Eun Kim, Ju Won Kim, So Yeon Oh, Joo Young Ha, Mi Sun Ahn, Su Ee Lee, Min Hwan Kim, Kyong Hwa Park, Han Jo Kim, Eun Mi Lee, Su-Jin Koh, Kyoung Eun Lee, In Hae Park, Jin Hyun Park, Jong Gwon Choi, Yeon Hee Park, Yee Soo Chae, Miso Kim, Jae Ho Byun, Gyeong Won Lee, and Jee Hyun Kim more...
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Cancer ,medicine.disease ,Interim analysis ,Metastatic breast cancer ,Loading dose ,Clinical trial ,Trastuzumab ,Internal medicine ,medicine ,business ,Adverse effect ,Progressive disease ,medicine.drug - Abstract
Background: Prognosis of patients with HER-2 positive metastatic breast cancer (MBC) has been revolutionized with the development of dual antibodies targeting HER-2 and antibody-drug conjugate, but resistance to anti-HER-2 therapy is inevitable ultimately. PI3K-AKT-mTOR pathway aberration is known to be one of the resistance mechanisms. This randomized phase 2 pilot study evaluated safety and efficacy of Herzuma® (trastuzumab biosimilar) plus Gedatolisib (dual PI3K/mTORC inhibitor) in patients with HER-2 positive MBC who progressed after multiple lines of therapy. Methods: Patients with HER-2 positive MBC with known PIK3CA pathologic mutation or amplification whose disease progressed after more than two HER-2 directed therapy were enrolled in the study. They received Herzuma® (8mg/kg IV for 1st cycle loading dose, and then 6mg/kg IV every 3 weeks) plus Gedatolisib (180mg on D1, 8, 15 of every 21 days). We evaluated efficacy of the combination treatment as interim analysis. The data cutoff of this interim analysis was Aug 4, 2020. Results: As a pilot study, 15 patients were enrolled and followed for a median of 2.3 months. At data cutoff, 11 patients were eligible for response assessment. All patients were confirmed to have pathologic PIK3CA aberrations: H1047R, H1047L, E542Q, E542K, E453K, N345K, and PIK3CA amplification. Five patients reached partial response (PR) as their best response, three were stable disease (SD), and three had progressive disease (PD). All patients who have reached PR remain on investigational treatment at the data cutoff point, and the longest one is on treatment for 7.8 months. One of the SD patients ended treatment due to disease progression, and the other two have been undergoing treatment. Overall, response rate was 45.5% and disease control rate was 72.7%. No fatal adverse events related to trial medication were reported. Conclusion: In this phase 2 pilot study, Trastuzumab biosimilar plus Gedatolisib presented 45.5% of response rate with manageable toxicity in patients with HER-2 positive MBC with PIK3CA aberration. Clinical trial information: NCT03698383 Acknowledgement: this research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health &Welfare, Republic of Korea (Grant number: HI17C2206). Citation Format: Ju Won Kim, Hee Kyung Ahn, Jong Gwon Choi, Yee Soo Chae, Gyeong Won Lee, Keon Uk Park, Eun Mi Lee, Sung Hoon Sim, Jee Hyun Kim, Yeon Hee Park, Mi So Kim, Jin Hyun Park, Jeong Eun Kim, Han Jo Kim, Mi Sun Ahn, So Yeon Oh, Min Hwan Kim, Su-Jin Koh, Kyoung Eun Lee, Myoung Joo Kang, Jae Ho Byun, Joo young Ha, Jung Hye Kwon, Joo Young Jung, Su Ee Lee, In Hae Park, Kyong Hwa Park. Phase II pilot study of trastuzumab biosimilar (herzuma®) plus gedatolisib in patients with HER-2 positive metastatic breast cancer who progressed after 2 or more HER-2 directed chemotherapy [KM-10A/KCSG18-13 interim analysis] [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS11-39. more...
- Published
- 2021
- Full Text
- View/download PDF
37. Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
- Author
-
Hee Kyung Ahn, Seok Yun Kang, Seock-Ah Im, Gun Min Kim, Jee Hyun Kim, Yeon Hee Park, In Hae Park, Ji Yun Lee, and Kyung Hae Jung
- Subjects
Oncology ,Cancer Research ,Pyridines ,Receptor, ErbB-2 ,medicine.medical_treatment ,CDK4/6 inhibitor ,Piperazines ,chemistry.chemical_compound ,Exemestane ,Antineoplastic Combined Chemotherapy Protocols ,Multicenter Studies as Topic ,skin and connective tissue diseases ,Mastectomy ,Randomized Controlled Trials as Topic ,education.field_of_study ,Hazard ratio ,Middle Aged ,Metastatic breast cancer ,Progression-Free Survival ,Receptors, Estrogen ,Chemotherapy, Adjuvant ,Original Article ,Female ,Receptors, Progesterone ,medicine.drug ,Endocrine therapy ,Adult ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,Population ,Breast Neoplasms ,Palbociclib ,Capecitabine ,Clinical Trials, Phase II as Topic ,Internal medicine ,Breast Cancer ,medicine ,Humans ,education ,Protein Kinase Inhibitors ,Chemotherapy ,business.industry ,medicine.disease ,Androstadienes ,Tamoxifen ,chemistry ,Neoplasm Recurrence, Local ,business - Abstract
Purpose YoungPEARL (KCSG-BR15-10) trial demonstrated a significant progression-free survival (PFS) benefit for premenopausal patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer (MBC) for palbociclib plus exemestane with ovarian function suppression compared to capecitabine. However, the number of tamoxifen-sensitive premenopausal patients was small because most recurrences occurred early during adjuvant endocrine therapy (ET), with tamoxifen being the only drug used; hence, the data for these patients were limited. Here we present a subgroup analysis according to tamoxifen sensitivity from the YoungPEARL study. Materials and Methods Patients were randomized 1:1 to receive palbociclib+ET (oral exemestane 25 mg/day for 28 days, palbociclib 125 mg/day for 21 days, plus leuprolide 3.75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1,250 mg/m2 twice daily for 14 days every 3 weeks). Tamoxifen resistance was defined as: relapse while on adjuvant tamoxifen, relapse within 12 months of completing adjuvant tamoxifen, or progression while on first-line tamoxifen within 6 months for MBC.Results In total, 184 patients were randomized and 178 were included in the modified intention-to-treat population. PFS improvement in the palbociclib+ET group was observed in tamoxifen-sensitive patients (hazard ratio, 0.38; 95% confidence interval, 0.12 to 1.19). Furthermore, palbociclib+ET prolonged median PFS compared with capecitabine in tamoxifen-sensitive (20.5 months vs. 12.6 months) and tamoxifen-resistant (20.1 months vs. 14.5 months) patients. Palbociclib+ET demonstrated a higher rate of objective response, disease control, and clinical benefit in tamoxifen-sensitive patients. Conclusion This post hoc exploratory analysis suggests that palbociclib+ET is a promising therapeutic option for premenopausal HR+/HER2– MBC patients irrespective of tamoxifen sensitivity. more...
- Published
- 2020
38. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)
- Author
-
Hee Kyung Ahn, Eun Joo Kang, Seong Hoon Shin, Sung-Bae Kim, Y. Lee, Keon Uk Park, Jung Hye Kwon, Kyoung Eun Lee, Keun Wook Lee, Hwan Jung Yun, Hye Ryun Kim, Min Kyoung Kim, Jin-Soo Kim, Jin-Hyuk Choi, and Bhumsuk Keam more...
- Subjects
0301 basic medicine ,Oncology ,Male ,Cancer Research ,medicine.medical_treatment ,Cetuximab ,Docetaxel ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Squamous cell carcinoma ,Antineoplastic Combined Chemotherapy Protocols ,Locally advanced head and neck cancer ,Aged, 80 and over ,Chemoradiotherapy ,Induction Chemotherapy ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Combined Modality Therapy ,Progression-Free Survival ,Survival Rate ,Head and Neck Neoplasms ,030220 oncology & carcinogenesis ,Female ,Fluorouracil ,medicine.drug ,Research Article ,Adult ,medicine.medical_specialty ,Antimetabolites, Antineoplastic ,Strategy ,lcsh:RC254-282 ,03 medical and health sciences ,Young Adult ,Internal medicine ,Genetics ,medicine ,Humans ,Aged ,Retrospective Studies ,business.industry ,Squamous Cell Carcinoma of Head and Neck ,Induction chemotherapy ,Retrospective cohort study ,Multidisciplinary treatment ,medicine.disease ,Head and neck squamous-cell carcinoma ,Radiation therapy ,Regimen ,030104 developmental biology ,Nasopharyngeal carcinoma ,Cisplatin ,business ,Follow-Up Studies - Abstract
Background By investigating treatment patterns and outcomes in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), we aimed at providing valuable insights into the optimal therapeutic strategy for physicians in real-world practice. Methods This is a multi-institutional study enrolled the patients with stage III to IVB LA-HNSCC, except for nasopharyngeal carcinoma, from 2004 to 2015 in thirteen referral hospitals capable of multidisciplinary care. Results A total of 445 LA-HNSCC patients were analyzed. The median age was 61 years (range, 24–89). The primary tumor location was the oropharynx in 191 (43%), oral cavity in 106 (24%), hypopharynx in 64 (14%), larynx in 57 (13%) and other sites in 27 (6%). The most common stage was T2 in 172 (39%), and N2 in 245 (55%). Based on treatment intents, 229 (52%) of the patients received definitive concurrent chemoradiotherapy (CCRT) and 187 (42%) underwent surgery. Approximately 158 (36%) of the study population received induction chemotherapy (IC). Taken together, 385 (87%) of the patients underwent combined therapeutic modalities. The regimen for definitive CCRT was weekly cisplatin in 58%, 3-weekly cisplatin in 28% and cetuximab in 3%. The preferred regimen for IC was docetaxel with cisplatin in 49%, and docetaxel, cisplatin plus fluorouracil in 27%. With a median follow-up of 39 months, one-year and two-year survival rates were 89 and 80%, respectively. Overall survival was not significantly different between CCRT and surgery group (p = 0.620). Conclusions In patients with LA-HNSCC, the majority of patients received combined therapeutic modalities. Definitive CCRT, IC then definitive CCRT, and surgery followed by adjuvant CCRT or radiotherapy are the preferred multidisciplinary strategies in real-world practice. more...
- Published
- 2020
- Full Text
- View/download PDF
39. Non-scanning 2-D Laser Cutting of Polyimide by Using a Computer-Generated Hologram
- Author
-
Seongwoo Cha, Hong Jin Kong, Hwihyeong Lee, and Hee Kyung Ahn
- Subjects
010302 applied physics ,Materials science ,business.industry ,Laser cutting ,Process (computing) ,Holography ,General Physics and Astronomy ,Drilling ,02 engineering and technology ,021001 nanoscience & nanotechnology ,Laser ,01 natural sciences ,law.invention ,Optics ,law ,0103 physical sciences ,Tool wear ,0210 nano-technology ,business ,Throughput (business) ,Polyimide - Abstract
Laser processing is an effective way for precisely and accurately removing a small region of materials without tool wear. Conventional laser processing, which has a limitation on the processing speed, is performed by scanning a single spot on a target material. For improving its speed, a high-power laser beam can be spatially distributed using a hologram to simultaneously process a two-dimensional area. This technique has been used in experiments such as drilling, patterning, etc. However, as far as we know, due to several difficulties, no experiments have been reported that apply the holographic technique to non-scanning cutting with a single hologram. In this research, we experimentally performed non-scanning 2-D laser cutting of a polyimide film by using a single computer-generated hologram (CGH) and a high-power laser of 120 W. To do this, we designed a CGH to reconstruct twelve lines in a 24 mm × 23 mm area. This was then fabricated with fused silica so that it would not be damaged by the high-power laser. This method makes possible the achievement of a high throughput in a material cutting process by utilizing a high-power laser efficiently. more...
- Published
- 2020
- Full Text
- View/download PDF
40. Oligomerisation of a plant helper NLR requires cell-surface and intracellular immune receptor activation
- Author
-
Joanna M. Feehan, Junli Wang, Xinhua Sun, Jihyeon Choi, Hee-Kyung Ahn, Bruno Pok Man Ngou, Jane E. Parker, and Jonathan D. G. Jones
- Subjects
Multidisciplinary - Abstract
Plant disease resistance involves both detection of microbial molecular patterns by cell-surface pattern recognition receptors and detection of pathogen effectors by intracellular NLR immune receptors. NLRs are classified as sensor NLRs, involved in effector detection, or helper NLRs required for sensor NLR signaling. TIR-domain-containing sensor NLRs (TNLs) require helper NLRs NRG1 and ADR1 for resistance, and helper NLR activation of defense requires the lipase-domain proteins EDS1, SAG101, and PAD4. Previously, we found that NRG1 associates with EDS1 and SAG101 in a TNL activation-dependent manner [X. Sun et al. , Nat. Commun. 12 , 3335 (2021)]. We report here how the helper NLR NRG1 associates with itself and with EDS1 and SAG101 during TNL-initiated immunity. Full immunity requires coactivation and mutual potentiation of cell-surface and intracellular immune receptor-initiated signaling [B. P. M. Ngou, H.-K. Ahn, P. Ding, J. D. G. Jones, Nature 592 , 110–115 (2021), M. Yuan et al. , Nature 592 , 105–109 (2021)]. We find that while activation of TNLs is sufficient to promote NRG1–EDS1–SAG101 interaction, the formation of an oligomeric NRG1–EDS1–SAG101 resistosome requires the additional coactivation of cell-surface receptor-initiated defense. These data suggest that NRG1–EDS1–SAG101 resistosome formation in vivo is part of the mechanism that links intracellular and cell-surface receptor signaling pathways. more...
- Published
- 2022
- Full Text
- View/download PDF
41. Effector-dependent activation and oligomerization of NRC helper NLRs by Rpi-amr3 and Rpi-amr1
- Author
-
Hee-Kyung Ahn, Xiao Lin, Andrea Carolina Olave-Achury, Lida Derevnina, Mauricio P Contreras, Jiorgos Kourelis, Sophien Kamoun, and Jonathan D G Jones
- Abstract
Plant pathogens compromise crop yields. Plants have evolved robust innate immunity that depends in part on intracellular Nucleotide-binding, Leucine Rich-Repeat (NLR) immune receptors that activate defense responses upon detection of pathogen-derived effectors. Most “sensor” NLRs that detect effectors require the activity of “helper” NLRs, but how helper NLRs support sensor NLR function is poorly understood. Many Solanaceae NLRs require the NRC (NLR-Required for Cell death) class of helper NLRs. We show here that Rpi-amr3, a sensor NLR from Solanum americanum, detects AVRamr3 from the potato late blight pathogen, Phytophthora infestans, and activates oligomerization of the helper NLR NRC2 into a high-molecular weight resistosome. The NRC2 resistosome also forms upon recognition of P. infestans effector AVRamr1 by another sensor NLR, Rpi-amr1. The ATP-binding motif of Rpi-amr3 is required for NRC2 resistosome formation, but not for interaction with the cognate effector. The NRC2 resistosome can be activated by AVRamr3 homologs from other Phytophthora species. Mechanistic understanding of NRC resistosome formation will underpin engineering crops with durable disease resistance. more...
- Published
- 2022
- Full Text
- View/download PDF
42. Sensor NLR immune proteins activate oligomerization of their NRC helper
- Author
-
Mauricio P. Contreras, Hsuan Pai, Yasin Tumtas, Cian Duggan, Enoch Lok Him Yuen, Angel Vergara Cruces, Jiorgos Kourelis, Hee-Kyung Ahn, Chih-Hang Wu, Tolga O. Bozkurt, Lida Derevnina, and Sophien Kamoun more...
- Abstract
Nucleotide-binding domain and leucine-rich repeat (NLR) immune receptors are important components of plant and metazoan innate immunity that can function as individual units or as pairs or networks. Upon activation, NLRs form multiprotein complexes termed resistosomes or inflammasomes. Whereas metazoan paired NLRs, such as NAIP/NLRC4, activate into hetero-complexes, the molecular mechanisms underpinning activation of plant paired NLRs, especially whether they associate in resistosome hetero-complexes is unknown. In asterid plant species, the NLR required for cell death (NRC) immune receptor network is composed of multiple resistance protein sensors and downstream helpers that confer immunity against diverse plant pathogens. Here, we show that pathogen effector-activation of the NLR proteins Rx (confers virus resistance) and Bs2 (confers bacterial resistance) leads to oligomerization of the helper NLR NRC2. Activated Rx does not oligomerize or enter into a stable complex with the NRC2 oligomer and remains cytoplasmic. In contrast, activated NRC2 oligomers accumulate in membrane-associated puncta. We propose an activation-and-release model for NLRs in the NRC immune receptor network. This points to a distinct activation model compared to mammalian paired NLRs. more...
- Published
- 2022
- Full Text
- View/download PDF
43. Preliminary Attainability Assessment of Real-World Data for Answering Major Clinical Research Questions in Breast Cancer Brain Metastasis: Framework Development and Validation Study
- Author
-
Min Jeong Kim, Hyo Jung Kim, Danbee Kang, Hee Kyung Ahn, Soo-Yong Shin, Seri Park, Juhee Cho, and Yeon Hee Park
- Subjects
Health Informatics - Abstract
Background In recent decades, real-world evidence (RWE) in oncology has rapidly gained traction for its potential to answer clinical questions that cannot be directly addressed by randomized clinical trials. Integrating real-world data (RWD) into clinical research promises to contribute to more sustainable research designs, including extension, augmentation, enrichment, and pragmatic designs. Nevertheless, clinical research using RWD is still limited because of concerns regarding the shortage of best practices for extracting, harmonizing, and analyzing RWD. In particular, pragmatic screening methods to determine whether the content of a data source is sufficient to answer the research questions before conducting the research with RWD have not yet been established. Objective We examined the PAR (Preliminary Attainability Assessment of Real-World Data) framework and assessed its utility in breast cancer brain metastasis (BCBM), which has an unmet medical need for data attainability screening at the preliminary step of observational studies that use RWD. Methods The PAR framework was proposed to assess data attainability from a particular data source during the early research process. The PAR framework has four sequential stages, starting with clinical question clarification: (1) operational definition of variables, (2) data matching (structural/semantic), (3) data screening and extraction, and (4) data attainability diagramming. We identified 5 clinical questions to be used for PAR framework evaluation through interviews and validated them with a survey of breast cancer experts. We used the Samsung Medical Center Breast Cancer Registry, a hospital-based real-time registry implemented in March 2021, leveraging the institution’s anonymized and deidentified clinical data warehouse platform. The number of breast cancer patients in the registry was 45,129; it covered the period from June 1995 to December 2021. The registry consists of 24 base data marts that represent disease-specific breast cancer characteristics and care pathways. The outcomes included screening results of the clinical questions via the PAR framework and a procedural diagram of data attainability for each research question. Results Data attainability was tested for study feasibility according to the PAR framework with 5 clinical questions for BCBM. We obtained data sets that were sufficient to conduct studies with 4 of 5 clinical questions. The research questions stratified into 3 types when we developed data fields for clearly defined research variables. In the first, only 1 question could be answered using direct data variables. In the second, the other 3 questions required surrogate definitions that combined data variables. In the third, the question turned out to be not feasible for conducting further analysis. Conclusions The adoption of the PAR framework was associated with more efficient preliminary clinical research using RWD from BCBM. Furthermore, this framework helped accelerate RWE generation through clinical research by enhancing transparency and reproducibility and lowering the entry barrier for clinical researchers. more...
- Published
- 2023
- Full Text
- View/download PDF
44. Abstract P5-03-14: Prevalence of germline BRCA mutations in unselected Korean patients with HER2-negative breast cancer: A Prospective cohort study
- Author
-
Hee Kyung Ahn, Jee Hung Kim, Mirae Kim, Seri Park, Su-Jin Koh, Joo Hyuk Sohn, Myoung Joo Kang, Kyung Hae Jung, Kyoung Eun Lee, Jieun Lee, Sung Ae Koh, Yee Soo Chae, Jae Ho Byun, In Hae Park, Hee-Jun Kim, Jee Hyun Kim, Han Jo Kim, Joo Young Jung, Jung Lim Lee, Yoon Young Cho, Kyong Hwa Park, Ji-Yeon Kim, Seock-Ah Im, and Yeon Hee Park more...
- Subjects
Cancer Research ,Oncology - Abstract
Backgrounds Since OlympiAD study, National Comprehensive Cancer Network guideline recommends assessment of germline BRCA1/2 mutation in all patients with recurrent or metastatic breast cancer to identify candidates for PARP inhibitor therapy, which is not always possible in clinical practice due to limited resources for testing. Data on the prevalence of gBRCA mutation is still lacking, especially in patients with non-high risk for hereditary breast and ovarian cancer syndrome. In this study, we investigated prevalence of gBRCA mutation in unselected Korean patients with HER2-negative advanced BC in a prospective cohort and analyzed oncologic outcome. Methods Eligible patients were diagnosed with HER2-negative advanced BC and had initiated palliative systemic treatment. Peripheral blood was prospectively drawn from each patient and gBRCA mutation status was assessed by next generation sequencing using NGeneBio BRCAaccuTest®. In 100 patients, somatic mutations including BRCA1/2 from tumor tissue were investigated using targeted panel sequencing. To estimate the prevalence of gBRCA mutation with margin of error to be no more than ±4% at the 95% confidence interval in a population size of 20,000, 583 patients were to be enrolled. Results A total of 583 patients were enrolled between Oct 2019 and Mar 2022, and the prevalence of gBRCA mutation was analyzed in 570 patients, excluding ineligible patients. Median age was 54 years old (range 26-87) and 567 patients were female. 475 patients had HR+/HER2- BC and 94 patients had triple negative breast cancer (TNBC). The overall prevalence of gBRCA1/2 pathogenic mutation was 7.3% (42/570) in unselected patients. The prevalence of gBRCA1 mutation was 1.6%(9/570) overall, 0.8%(4/475) in HR+/HER2- BC, and 5.3%(5/94) in TNBC. The prevalence of gBRCA2 mutation was 5.8%(33/570) overall, 6.3%(30/475) in HR+/HER2- BC, 3.2%(3/94) in TNBC. Prevalence in low risk TNBC (>60 years at first BC diagnosis, no known family history of relevant cancer and unilateral breast cancer) was 10.5% (2/19, all 2 patients had gBRCA2 mutation). Prevalence in low risk HR+/HER2- (>40 years at first BC diagnosis, no known family history of relevant cancer and unilateral breast cancer) was 5.9% (18/307, 17 patients had gBRCA2 mutation). The overall prevalence of gBRCA1/2 pathogenic mutation in Korean patients with low risk HER2-negative advanced BC was 6.1%. The result of somatic mutation, treatment patterns and clinical outcome according to gBRCA1/2 mutation will be further analyzed. Conclusions The prevalence of gBRCA mutation among Korean patients with HER2-negative advanced BC classified as low risk (6.1%) in this study supports routine testing of gBRCA mutation in this population. Citation Format: Hee Kyung Ahn, Jee Hung Kim, Mirae Kim, Seri Park, Su-Jin Koh, Joo Hyuk Sohn, Myoung Joo Kang, Kyung Hae Jung, Kyoung Eun Lee, Jieun Lee, Sung Ae Koh, Yee Soo Chae, Jae Ho Byun, In Hae Park, Hee-Jun Kim, Jee Hyun Kim, Han Jo Kim, Joo Young Jung, Jung Lim Lee, Yoon Young Cho, Kyong Hwa Park, Ji-Yeon Kim, Seock-Ah Im, Yeon Hee Park. Prevalence of germline BRCA mutations in unselected Korean patients with HER2-negative breast cancer: A Prospective cohort study [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-03-14. more...
- Published
- 2023
- Full Text
- View/download PDF
45. Abstract P4-02-27: Preliminary Attainability Assessment of Real-World Data for Answering Clinical Questions about Breast Cancer Brain Metastases
- Author
-
Min-Jeong Kim, Hyo Jung Kim, Danbee Kang, Hee Kyung Ahn, Soo-Yong Shin, Seri Park, Juhee Cho, and Yeon Hee Park
- Subjects
Cancer Research ,Oncology - Abstract
Background Brain metastases is one of breast cancer’s leading causes of death, and the incidence is increasing with advances in diagnosis and treatment techniques. Nevertheless, these patients have fewer opportunities to participate in prospective randomized clinical trials because of the design challenges of increasing target population heterogeneity or differentiating the definition of endpoints and how the endpoints are evaluated. Real-world data has the potential that reaches the information at a blinded area of RCT approaches. In recent years, observational studies using real-world data have gotten attention for their capability to enhance an understanding of hard-to-reach RCT approaches. However, the yet incomplete gold standard of the study protocol and the unpredictable ’hidden labor’ of secondary use of clinical data become barriers to clinical researchers. In the study, we demonstrate data attainability assessment focused on clinicians’ clinical unmet needs in breast cancer brain metastases (BCBM) as a preliminary step of the observational study for screening study feasibility on a certain data source. Methods A breast cancer registry based on the clinical data warehouse (CDW) of Samsung Medical Center has been used as the data source (N=45,219, up to 31 Dec 2021). A total of 5 clinical questions (CQ) were presented as the result of the interview of two breast cancer experts about BCBM for the study (Table 1). Additionally, we conducted an attainability assessment for the population size and core variables constrained by a clinical question and a survey of 7 breast cancer clinicians for evaluation of the recognized clinical significance and research methods’ suitability for each CQ. A working group was formed for data attainability tests withal a person with experience in clinical research for at least several years across interdisciplinary areas, including clinical expertise, medical informatics, and epidemiology. For the first step, we declare the operational definition for the study population and core variables in which the research question is inherent conceptually. And appropriate data fields and value sets are figured out from the data set. Data attainability is examined via RWD extraction on the population size and availability of core variables. Result The collected five CQs were mostly about the relationship between brain metastases, systemic metastases, and systemic treatments. Other CQs were related to the relationship between brain metastases incidence and the type of neoadjuvant treatment or patients’ described symptoms. Assessment of the importance of clinical questions aligned well, especially for the questions with higher scores. (r=- · 98) For CQ E, filtered out not to fit the SMC BCR dataset at the early stage of the data attainability screening process due to lack of explicit data field or semantically related value sets for one of the core variables, ‘neurological symptom.’ For CQ A, B, and D, we could confirm enough population size and dataset for conducting the study, but additional logical reconstruction of data elements had needed. For example, we used the ‘clinical subtype’ variable, which is provided from SMC BCR, as pre-processed feature variable using an expert-knowledge-based algorithm. For CQ C, we were able to obtain pertinent data for the study only with direct data field match and explicit code set definition. Conclusion To effectively use CDW, the variables have to be interpreted and defined in a clinically meaningful way with the cooperation of clinicians and data science experts. For observational studies based on RWD, understanding the data source contents and clarifying the research question enough to translate to the data level is essential. The step-by-step protocol presented in the study could be applied to the other clinical researcher using RWD at preliminary feasibility screening. Table 1. List of clinical questions from expert interviews Citation Format: Min-Jeong Kim, Hyo Jung Kim, Danbee Kang, Hee Kyung Ahn, Soo-Yong Shin, Seri Park, Juhee Cho, Yeon Hee Park. Preliminary Attainability Assessment of Real-World Data for Answering Clinical Questions about Breast Cancer Brain Metastases [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-02-27. more...
- Published
- 2023
- Full Text
- View/download PDF
46. Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
- Author
-
Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se Jin Jang, Dae Young Zang, Tae Won Kim, Jin Hyoung Kang, and Jee Hyun Kim more...
- Subjects
Cancer Research ,Precision medicine ,High-Throughput Nucleotide Sequencing ,Molecular tumor board ,Medical Oncology ,Special Article ,Oncology ,Advanced solid cancer ,Neoplasms ,Practice Guidelines as Topic ,Republic of Korea ,Next-generation sequencing ,Humans ,Societies, Medical ,Genomic alterations - Abstract
Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea’s public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion. more...
- Published
- 2021
47. The Effects of Envy on Preference for Self-improvement Products
- Author
-
Rankyung Lee, Seung Hwa Kim, and Hee-Kyung Ahn
- Subjects
Self improvement ,Psychology ,Social psychology - Abstract
본 연구는 선망이라는 감정이 자기향상제품에 대한 선호에 영향을 줄 수 있음을 보여준다. 선망은 선의적 선망(benign envy)과 악의적 선망(malicious envy)으로 구분되는데, 본 연구에서는 특히 선망을 느낀 상황과는 관련이 없는 맥락에서 소비자가 자기향상제품에 대한 선호를 보이는지에 대하여 살펴보고자 하였다. 나아가 메시지를 제시하는 방식에 따라 선망이 자기향상제품의 선호에 미치는 영향이 다르게 나타날 수 있는지 알아보고자 하였다. 실험 결과, 악의적 선망을 느낀 경우보다 선의적 선망을 느낀 경우에 자기향상제품에 대한 선호도가 높은 것으로 나타났다. 또한 메시지 프레이밍의 조절효과가 확인되었다. 메시지가 긍정적으로 주어졌을 때에는 악의적 선망을 느낀 경우보다 선의적 선망을 느낀 경우에 자기향상제품에 대한 선호가 높게 나타났다. 하지만 메시지가 부정적으로 제시되었을 때에는 악의적 선망을 느낀 경우와 선의적 선망을 느낀 경우 간 유의한 차이가 나타나지 않았다. 본 연구는 자기향상제품의 선호에 영향을 주는 선망의 효과를 살펴보고 이를 조절하는 메시지 프레이밍의 효과를 증명하였기에, 자기향상제품에 대한 효과적인 광고 메시지 전략 수립에 활용될 수 있을 것이라 기대한다. more...
- Published
- 2020
- Full Text
- View/download PDF
48. The Influence of Temperature on Identifiable Victim Effects
- Author
-
카카오 Vx 마케팅기획팀 한양대학교 일반대학원 경영학과 석사, Jeong Chul Shin, and Hee-Kyung Ahn
- Subjects
Embodied cognition ,Contrast effect ,Psychology ,Cognitive psychology - Published
- 2020
- Full Text
- View/download PDF
49. When Do Consumers Purchase Self-improvement Products?: The Interplay between the Type of Self-improvement and Envy
- Author
-
Lee, Rankyung, Seung-Hwa Kim, and Hee-Kyung Ahn
- Subjects
Self improvement ,Ethical consumption ,Psychology ,Social psychology - Published
- 2020
- Full Text
- View/download PDF
50. Practice patterns of multidisciplinary team meetings in Korean cancer care and patient satisfaction with this approach
- Author
-
Seungtaek Lim, Chi Hoon Maeng, Bong-Seog Kim, Hee Kyung Ahn, Do Yeun Kim, and Sung Yong Oh
- Subjects
medicine.medical_specialty ,patient satisfaction ,Multidisciplinary team ,Patient Care Planning ,03 medical and health sciences ,Hemato-Oncology ,0302 clinical medicine ,Patient satisfaction ,Breast cancer ,Neoplasms ,Republic of Korea ,medicine ,Humans ,Prospective Studies ,Radiation treatment planning ,multidisciplinary team ,Patient Care Team ,Practice patterns ,business.industry ,Cancer ,University hospital ,medicine.disease ,medical oncology ,Family medicine ,Cohort ,treatment outcome ,Medicine ,030211 gastroenterology & hepatology ,Original Article ,business - Abstract
Background/Aims: The multidisciplinary team (MDT) approach is a cornerstone of clinical oncology. This study investigated the current state of MDT care, in cluding patient satisfaction, in Korea. Methods: We obtained the annual number of cancer patients who have received MDT care since 2014 from the registry of the Health Insurance Review and As sessment Service (HIRA). In addition, patients who received MDT care from Au gust 2014 to May 2017 at four university hospitals were further characterized, and patient satisfaction was measured prospectively using a patient-reported ques tionnaire. Results: The total number of patients who received MDT care increased from 2014 to 2016 (2,113 to 9,998 patients, respectively) in the HIRA Cohort. The type of cancer that most often required MDT was breast cancer (23.8%), followed by col orectal cancer (19.1%). In the Representative Cohort (n = 1,032), MDT was request ed by the surgeon more than half the time (55.7%). The main focus of MDT was decision making for further treatment planning (99.0%). The number of doctors participating in the MDT was usually five (70.0%). After initiating an MDT ap proach, the treatment plan changed for 17.4% of patients. Among these patients, 359 completed a prospective satisfaction survey regarding their MDT care. The overall satisfaction with the MDT approach was very high, with an average score of 9.6 out of 10 points. Conclusions: The application of MDT care is a rapidly growing trend in clini cal oncology, and shows high patient satisfaction. Further research is needed to determine which types of cancer patients could benefit most from MDT, and to enable MDT care to operate more efficiently so that it may expand successfully throughout Korea. more...
- Published
- 2020
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.